Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC

Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC

Thursday, April 8, 2021
Webinar -- 4:00 PM CET
https://www.clinicaloptions.com/ADCLung2021Join1

Agenda

Welcome, Introduction, Polling Questions

Introduction: Novel ADCs for Treatment of NSCLC – Professor Smit

Activity of ADCs in Clinical Trials for Lung Cancer

  • HER2-altered NSCLC, HER3-positive NSCLC – Dr. Yu
  • TROP-2–positive NSCLC, CEACAM5, c-Met–positive NSCLC – Dr. Planchard

Panel Discussion and Clinical Pearls: Integrating ADC Therapy in NSCLC

Summary, Final Thoughts, Audience Q&A

Faculty

Program Director
Egbert F. Smit, MD, PhD

Professor
Department of Pulmonary Diseases
Leiden University Medical Center
Leiden, Netherlands
Department of Thoracic Oncology
Netherlands Cancer Institute
Amsterdam, Netherlands

Faculty
David Planchard, MD, PhD

Associate Professor of Medicine
Department of Medicine at Gustave Roussy
Villejuif, France

Faculty
Helena Yu, MD

Assistant Attending 
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners to integrate new and emerging prognostic and predictive biomarkers into NSCLC treatment paradigms.

Target Audience
This program is intended for global medical oncologists, pathologists and other healthcare providers who care for patients with lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Discuss the clinical rationale for assessing HER2, HER3, and TROP2 in the metastatic setting for NSCLC
  • Appraise the available clinical data on HER2-, HER3-, and TROP2-targeted antibody–drug conjugates in NSCLC
  • Plan therapeutic strategies for appropriate patients with HER2-altered NSCLC
  • Identify patients eligible to enroll on important ongoing clinical trials based evaluating novel HER2-, HER3-, and TROP2-targeted therapies in breast, gastrointestinal, and lung cancers

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.